BMO Capital Markets Reaffirms "Market Perform" Rating for Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report)'s stock had its "market perform" rating reissued by BMO Capital Markets in a research report issued to clients and investors on Tuesday, Marketbeat.com reports.

JSPR has been the topic of a number of other reports. HC Wainwright reduced their price target on shares of Jasper Therapeutics from $40.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday. Royal Bank Of Canada cut shares of Jasper Therapeutics from an "outperform" rating to a "sector perform" rating and set a $5.00 target price on the stock. in a report on Tuesday. BTIG Research cut their target price on shares of Jasper Therapeutics from $64.00 to $20.00 and set a "buy" rating on the stock in a report on Monday. Cantor Fitzgerald restated a "neutral" rating on shares of Jasper Therapeutics in a report on Monday. Finally, William Blair restated a "market perform" rating on shares of Jasper Therapeutics in a report on Monday. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $29.75.

Jasper Therapeutics Stock Down 4.9%

Shares of JSPR stock traded down $0.15 during trading on Tuesday, hitting $2.89. The company had a trading volume of 2,345,385 shares, compared to its average volume of 375,228. The stock's 50-day moving average is $5.32 and its two-hundred day moving average is $6.63. The stock has a market capitalization of $43.41 million, a price-to-earnings ratio of -0.55 and a beta of 2.69. Jasper Therapeutics has a 52 week low of $2.27 and a 52 week high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24). On average, research analysts predict that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC purchased a new stake in Jasper Therapeutics in the first quarter valued at about $46,000. Corton Capital Inc. purchased a new stake in Jasper Therapeutics in the first quarter valued at about $113,000. Wells Fargo & Company MN raised its stake in shares of Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after purchasing an additional 3,828 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Jasper Therapeutics in the fourth quarter worth about $223,000. Finally, Tema Etfs LLC purchased a new position in shares of Jasper Therapeutics in the fourth quarter worth about $266,000. Institutional investors own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.